Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $23.00.

Several research firms have issued reports on AURA. BTIG Research upped their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright boosted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Scotiabank upped their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the sale, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,259 shares of company stock valued at $780,699 over the last three months. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Long Focus Capital Management LLC lifted its stake in Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after acquiring an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. lifted its stake in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares during the period. Dimensional Fund Advisors LP increased its position in Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Aura Biosciences in the third quarter valued at approximately $169,000. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Up 2.4 %

Shares of AURA stock opened at $11.14 on Tuesday. The firm has a market capitalization of $552.66 million, a price-to-earnings ratio of -6.22 and a beta of 0.33. The firm’s 50 day moving average is $9.57 and its 200-day moving average is $8.44. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.